胃肠癌术后ICU生命支持使用趋势与结局
基于Epic Cosmos数据库2016至2025年376,503例成人胃肠癌手术患者,术后ICU入住率为21.8%,其中88.6%接受生命支持干预。ICU入住率下降8.4%,而生命支持使用率上升24.2%,生命支持与住院延长、并发症、30天死亡率和非居家出院显著相关。
要点
- 胃肠癌术后ICU入住率下降但生命支持干预使用率上升,提示术后重症照护更集中于高 acuity 患者。
- 食管癌手术较结直肠癌手术生命支持使用 odds 更高(aOR 2.42,95%CI 2.16–2.72)。
- 生命支持使用与30天死亡率升高独立相关(aOR 2.82,95%CI 2.50–3.19)。
核心结论
- 胃肠癌术后ICU使用减少而生命支持干预增加,反映术后重症照护选择性集中。
- 生命支持干预使用与不良短期结局强相关,可作为术后严重度标志用于风险分层和重症资源规划。
研究设计与样本
- 基于Epic Cosmos数据库2016至2025年的回顾性队列研究,纳入376,503例接受胃肠癌手术的成人患者。
- 采用多变量logistic回归评估生命支持使用的预测因素及与短期结局的关联,调整社会人口学和临床因素。
主要发现
- 376,503例患者中21.8%(82,076例)术后入住ICU,其中88.6%(72,702例)接受生命支持干预。
- 2016至2025年ICU入住率下降8.4%(95%CI 6.7–10.1),生命支持干预使用率上升24.2%(95%CI 22.8–25.6),均p<0.001。
- 生命支持使用在男性(59.3% vs 56.9%)、有合并症(53.7% vs 44.8%)和急诊就诊(24.7% vs 17.8%)患者中更频繁,均p<0.001。
- 与结直肠癌相比,食管癌手术生命支持使用aOR为2.42(95%CI 2.16–2.72)。
- 生命支持使用与住院延长(aOR 2.89,95%CI 2.66–3.14)、并发症(aOR 1.94,95%CI 1.85–2.04)、30天死亡率(aOR 2.82,95%CI 2.50–3.19)相关,居家出院 odds 降低(aOR 0.25,95%CI 0.23–0.27),均p<0.001。
临床怎么用
- 可将术后生命支持干预使用作为胃肠癌术后严重度标志,辅助围术期风险分层。
- 针对食管癌手术等高危人群,应优化围术期管理和重症资源规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative intensive care use after gastrointestinal cancer surgery may reflect evolving perioperative triage, yet national patterns of ICU admission and life-support intervention use remain poorly defined. STUDY DESIGN: Adults undergoing gastrointestinal cancer surgery identified in Epic Cosmos between 2016 and 2025 were identified. ICU admission and postoperative life-support intervention use, defined as invasive mechanical ventilation for greater than or equal to 24 consecutive hours or continuous vasopressor infusion during the index hospitalization, were assessed over time. Multivariable logistic regression evaluated predictors of life-support use and associations with short-term outcomes, adjusting for sociodemographic and clinical factors. RESULTS: Among 376,503 patients, 21.8% (n = 82,076) underwent postoperative ICU admission; 88.6% (n = 72,702) of individuals received life-support interventions. From 2016 to 2025, ICU admissions declined by 8.4% (95% CI 6.7 to 10.1), whereas life-support intervention use increased by 24.2% (95% CI 22.8 to 25.6; both p < 0.001). Life-support intervention use was more frequent among male patients (59.3% vs 56.9%), patients with comorbidity (53.7% vs 44.8%), and emergency presentations (24.7% vs 17.8%; all p < 0.001). Compared with colorectal cancer, esophageal cancer surgery had the highest odds of life-support intervention use (adjusted odds ratio [aOR] 2.42, 95% CI 2.16 to 2.72). Life-support intervention use was associated with prolonged hospitalization (aOR 2.89, 95% CI 2.66 to 3.14), complications (aOR 1.94, 95% CI 1.85 to 2.04), 30-day mortality (aOR 2.82, 95% CI 2.50 to 3.19), and lower odds of discharge home (aOR 0.25, 95% CI 0.23 to 0.27; all p < 0.001). CONCLUSIONS: After gastrointestinal cancer surgery, ICU use declined, whereas life-support intervention use increased, indicating more selective concentration of higher-acuity postoperative care. Life-support intervention use was strongly associated with adverse short-term outcomes and it may serve as a marker of postoperative severity to inform perioperative risk stratification and critical care resource planning.
引用
- Ekenze SO, Woldesenbet S, Chatzipanagiotou OP, et al. Life Support in the ICU: Outcomes among Patients Undergoing Gastrointestinal Cancer Surgery. J Am Coll Surg. 2026. PMID: 41972399. doi:10.1097/XCS.0000000000001973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。